Uloga čimbenika rasta fibroblasta 23 u akutnoj ozljedi bubrega by Sanja Sakan et al.
Acta Clin Croat,  Vol. 54,   No. 3,  2015 279
Acta Clin Croat 2015; 54:279-284 Original Scientific Paper
SIGNIFICANCE OF FIBROBLAST GROWTH FACTOR 23 IN 
ACUTE KIDNEY INJURY
Sanja Sakan1, Nikolina Bašić-Jukić2, Petar Kes2, Bojan Jelaković2, Daniela Bandić Pavlović3 
and Mladen Perić3
1Department of Anesthesiology and Intensive Care, Jordanovac Clinical Department of Thoracic Surgery; 2Clinical 
Department of Nephrology, Arterial Hypertension and Dialysis; 3Clinical Department of Anesthesiology, 
Resuscitation and Intensive Care, Zagreb University Hospital Center, Zagreb, Croatia 
SUMMARY – Acute kidney injury is a clinical syndrome associated with increased patient 
morbidity and mortality, as well as serious short-term and long-term consequences, especially in the 
perioperative period. Yet, patients having suffering from temporary acute kidney injury and achiev-
ing full recovery of kidney function usually complain of poor quality of life associated with loss of 
energy and limited physical activity. Therefore, there is a necessity for a novel biomarker of acute 
kidney injury with better features than currently used serum creatinine and urine output. So far, 
several investigations have demonstrated that the fibroblast growth factor 23 could be that desper-
ately searched novel biomarker of acute kidney injury. It cannot only detect kidney dysfunction at 
the time but also before the injury process begins. Moreover, serum levels of the fibroblast growth 
factor 23 can predict adverse progression of the kidney injury. However, the role of the fibroblast 
growth factor 23 in the acute but also in chronic kidney dysfunction is still a riddle that requires 
additional research to clarify it.
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Acute Kidney Injury
Acute kidney injury (AKI) is a frequent periopera-
tive complication and when it occurs independently, it 
increases patient morbidity, mortality and poor out-
come1-4. AKI is a clinical syndrome characterized by 
a sudden or persistent decrease in kidney function5-9. 
Due to reduction in the glomerular filtration rate 
(GFR), it is usually manifested as an increase in se-
rum creatinine or decrease in urine output. Although 
GFR is the accepted indicator of renal function, due 
to its difficult measurement it is usually assessed from 
serum creatinine levels and urine output10. However, 
elevation of serum creatinine and decrease in urine 
output do not allow clinicians to make a timely diag-
nosis of AKI, or to detect the site or severity of inju-
ry11. Serum creatinine is a renal biomarker the values 
of which vary widely with the patient clinical condi-
tion and therapy; thus, elevation in serum creatinine 
is usually delayed by several hours and occasionally 
by several days until reaching a steady value12. Also, 
about 50% of renal function must be lost prior to se-
rum creatinine starting to rise12. On the other hand, 
diuresis is not a sensitive renal biomarker because 
many hospitalized patients, especially critically ill, re-
ceive diuretics in their daily therapy, so oliguria can-
not be detected12. In addition, great attention should 
be paid to surgical patients that usually develop tem-
porary oliguria postoperatively due to perioperative 
multifactorial and complex hemodynamic and volume 
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disturbances, which lead to hypovolemia and subse-
quent renal hypoperfusion13-16. It is considered as a 
normal physiological renal response, so a clinician has 
to distinguish it from AKI.
Kidney is a robust organ and can put up with expo-
sure to many noxious impacts without any significant 
structural and functional renal impairment10. How-
ever, when this renal impairment does occur, it usu-
ally implies that severe multiorgan derangements have 
happened and that the patient’s condition is rather 
serious. Every clinician should be aware of a timely 
narrow therapeutic window of 24-48 hours between 
kidney submission to the high risk and noxious fac-
tors, and AKI genesis. In this important period, pre-
ventive and supportive measures must be undertaken 
and a novel biomarker of AKI should demonstrate its 
sensitivity and specificity. Therefore, small changes 
in serum creatinine values and urine output are in-
dependently associated with mortality and should be 
early detected and alert every clinician to start ap-
propriate patient monitoring and therapy17-20. Many 
studies have shown that even acute and mild kidney 
dysfunction can have severe sequels5-9. Moreover, 30% 
of patients who have experienced temporary uncom-
plicated AKI with full recovery of kidney function are 
at an increased risk of chronic kidney disease (CKD) 
development19,20,21.
The etiology and pathophysiology of AKI are 
complex and multifactorial22-24. Nevertheless, we 
can conclude that the major kidney risk factors are 
hypotension, ischemia and reperfusion, inflamma-
tion and nephrotoxins23,24. Their detrimental impact 
on the kidney function and structure can be revers-
ible, especially if therapeutic measures are applied in 
the narrow therapeutic renal window. Thereby, the 
main goal is to detect every insult to the kidney as 
early as possible. Therefore, a novel AKI biomarker 
is required. Till then, AKI should be always if pos-
sible predicted by the clinician and a supportive and 
nephroprotective strategy should be initiated13. These 
measures consist of optimization of hemodynamic pa-
rameters like maintaining systolic pressure >80 mm 
Hg, mean arterial pressure >65 mm Hg and renal 
perfusion pressure13. However, we consider that op-
timization of hemodynamic parameters is best man-
aged by timely and early goal directed therapy using 
less invasive hemodynamic monitoring if possible13. 
Another puzzle in daily management of AKI is when 
to initiate the supportive renal replacement therapy. 
Nowadays, there is still a tendency to postpone re-
nal replacement therapy as long as possible10. Renal 
replacement therapy deferring is usually justified by 
the patient hemodynamic instability, dialysis catheter 
associated complications, and activation of the patient 
immune and inflammation system due to bioincom-
patible dialysis membrane25,26. However, studies have 
demonstrated that late renal replacement therapy ini-
tiation is connected with increased patient mortal-
ity, longer duration of renal replacement therapy and 
hospital stay, compromised recovery of renal function, 
and in the end with a greater risk of progression to 
CKD and dialysis dependence27-31. On the other hand, 
early initiation of renal replacement therapy as soon as 
the patient develops stage 3 of AKI according to the 
RIFLE criteria is warranted by the benefit of avoiding 
exposure to the deleterious effects of metabolic waste 
products and abnormalities, or volume overload10. The 
major goal of the novel kidney biomarker would be to 
predict renal recovery and to give clear answer to the 
relevant question when to initiate and discontinue re-
nal replacement therapy10. By then, renal replacement 
therapy initiation will remain a clinical risk-benefit 
ratio decision based on the already developed compli-
cations manifested in the fluid, metabolic and electro-
lyte system of the individual patient10.
Thus, the desperately needed novel kidney bio-
marker should have the ability to early diagnose and 
predict the AKI course, identify the etiology, loca-
tion and severity of renal injury, provide individual 
patient risk stratification, define timing of renal re-
placement therapy initiation and discontinuation, and 
to be cost-effective, reliable and easy to use in clinical 
practice11,32,33.
Fibroblast Growth Factor 23
Fibroblast growth factor 23 (FGF23) is a bone 
produced novel hormone that for now has excellent 
features to be considered a new and early AKI bio-
marker34. It is generated and secreted primarily in 
bones by osteoblasts and osteocytes35. It pertains to 
the FGF19 subfamily and acts as an endocrine phos-
phaturic hormone, i.e. phosphatonine36. So, the major 
physiological role of FGF23 is to maintain phosphate 
homeostasis37. Preserving the systemic phosphate ho-
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meostasis is essential for the body. The reason is that 
various cellular functions ranging from cellular sig-
naling to enzymatic activities depend on the phos-
phate balance38. When this balance is disrupted, se-
vere vital organ system malfunctions arise38. Kidney 
is the organ responsible for preserving phosphate ho-
meostasis by a closed negative feedback loop between 
the kidneys, bones and parathyroid glands. When this 
loop becomes open, serum phosphate levels start to 
increase. So, hyperphosphatemia increases parathy-
roid hormone (PTH) and FGF23 secretion, which 
in turn enhance phosphaturia in a similar manner. 
As a result of kidney dysfunction, this negative feed-
back system is disrupted and phosphate serum levels 
augmentation continues. The only difference between 
PTH and FGF23 is that PTH increases phosphatu-
ria in a few hours, whereas FGF23 reacts after sev-
eral days39,40. The main phosphaturic mechanism of 
FGF23 is performed by inhibiting renal tubular re-
absorption of phosphate by reducing the number of 
sodium-dependent phosphate IIa and IIc cotransport-
ers in the apical brush border of the renal proximal 
tubule41-43. Everything we currently know about the 
FGF23 intracellular mechanism of action on renal 
phosphate excretion is that it has to connect with its 
main renal specific receptor FGFR1 together with 
the help of the Klotho transmembrane protein as a 
coreceptor to accomplish the effect41,42. Hence, the 
Klotho protein is the relevant factor that determines 
the FGF23 effects on target organs such as the kid-
ney, parathyroid glands, pituitary gland and choroid 
plexus in the brain44. Moreover, other avenues of 
maintaining phosphate homeostasis are decreasing in-
testinal phosphate absorption through direct action of 
reducing the number of sodium-dependent phosphate 
IIb cotransporters in the gastrointestinal mucosal api-
cal border, and indirectly through blocking calcitriol 
synthesis by reducing renal 1-alfa-hydroxylase activ-
ity and enhancing calcitriol catabolism by stimulating 
24-alfa hydroxylase activity34,36,45. The sequel of this 
avenue is diminished vitamin D-dependent intestinal 
phosphate absorption45. However, the FGF23 fashion 
of degradation is not well understood46. According 
to the literature, there are two forms of circulating 
FGF23 in the serum. One is intact and full-length 
form of the FGF23 which has biological activity 
and the other is inactive C-terminal fragment of the 
FGF23 without biological activity in the serum36. The 
assessed half-life of the intact FGF23 in the circula-
tion is about 58 minutes47.
Fibroblast Growth Factor 23 and Chronic Kidney 
Disease
Studies of the FGF23 in patients suffering from 
CKD have revealed that the capital drivers for the in-
creased FGF23 production are intestinal phosphate 
absorption after high oral phosphate entry, calcitriol, 
and PTH directly and indirectly by increased 1,25-
dihydroxy vitamin D3-dependent production36,48-51. 
Thus, FGF23 serum levels already significantly start 
to rise during early stages of CKD before serum phos-
phate derangements can be detected46,52,53. Thereby, 
in patients with end-stage CKD, they are hundreds- 
to thousands-fold higher than normal values46,52,53. 
Hence, we conclude that FGF23 could be the early 
biomarker of renal deterioration in the progress of 
CKD, and its serum values can predict the CKD 
outcome36. Also, FGF23 increased serum values 
are independently associated with higher mortality, 
therapy resistant secondary hyperparathyroidism, left 
ventricular hypertrophy and cardiovascular mortality 
in CKD patients38,52. This adverse effect of elevated 
FGF23 serum concentrations on cardiovascular sys-
tem is not well understood. Some evidence supports 
direct FGF23 toxicity on the cardiac and vascular 
endothelial function through low-affinity Klotho in-
dependent FGF receptors54,55. Other evidence dem-
onstrates the FGF23 cardiovascular toxicity due to 
disruption in the calcium-phosphate metabolism ho-
meostasis36. However, regardless of the mechanism of 
action, the result is the same.
Fibroblast Growth Factor 23 and Acute Kidney 
Injury
There are not so many studies on the role of FGF23 
in AKI, but recent studies have revealed that AKI is 
associated with raised serum levels of FGF2356-60. In 
addition, studies showed that elevated serum levels of 
FGF23 in AKI patients were connected with unfavor-
able outcome in terms of a significantly increased risk of 
death or need of renal replacement therapy57,58. Serum 
levels of FGF23 in AKI rise independently of the al-
ready mentioned drivers in CKD patients such as high 
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oral phosphate entry, calcitriol and PTH57. However, 
the precise mechanism of the increased FGF23 levels 
has not yet been elucidated. Increased production rath-
er than decreased elimination of FGF23 contributes 
to elevated levels of FGF23 in AKI, so impaired renal 
FGF23 scavenging due to reduction of the glomerular 
function units is not the major pathway for raising the 
FGF23 levels61. Also, another pathway that can con-
tribute to FGF23 serum elevation may be deficiency of 
the important FGF23 coreceptor Klotho in the injured 
kidney62. The Klotho deficiency leads to the FGF23 
resistance resulting in raised FGF23 serum levels. Be-
sides, enhanced bone production of FGF23 in AKI pa-
tients was demonstrated by immunohistochemical and 
Western blot analyses of the bones also as a mecha-
nism contributing to elevated FGF23 serum levels63,64. 
Yet, the responsible kidney driven factor for increased 
FGF23 bone production and the actual pathway of in-
teraction in this novel bone-kidney axis still remains 
obscure36. In addition, due to many difficulties in de-
tecting AKI in perioperative settings, FGF23 mani-
fested as a reliable biomarker of the acute kidney dys-
function since it begins to rise significantly within 24 
hours postoperatively57. Furthermore, one pilot study 
in pediatric population submitted to cardiac surgery 
indicated that elevated preoperative FGF23 serum lev-
els were also associated with a two-fold increased risk 
of AKI development, yet correlating with positive fluid 
balance, length of mechanical ventilation, and length 
of stay at the intensive care unit57.
Conclusion
In conclusion, the currently used kidney injury bio-
markers cannot detect AKI timely and usually their 
concentrations start to rise when the injury process is 
in the late phase. The goal of the new and early kid-
ney injury biomarker is to predict and diagnose AKI 
with the aim to start the nephroprotective treatment 
before the damage has happened. FGF23 could be a 
novel promising biomarker of AKI, especially in the 
complex perioperative period. However, additional 
research in the field is needed.
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Sažetak
ULOGA ČIMBENIKA RASTA FIBROBLASTA 23 U AKUTNOJ OZLJEDI BUBREGA
S. Sakan, N. Bašić-Jukić, B. Jelaković, P. Kes, D. Bandić-Pavlović i M. Perić
Akutna ozljeda bubrega je klinički sindrom povezan s povišenim rizikom pobola i smrtnosti te kratkotrajnim i dugo-
trajnim posljedicama, osobito kod bolesnika u perioperacijskom razdoblju. Zbog toga potreban je novi biomarker akutne 
bubrežne ozljede, bolje specifičnosti i osjetljivosti od serumske vrijednosti kreatinina i diureze. Nekoliko dosadašnjih rado-
va je pokazalo da čimbenik rasta fibroblasta 23 može pravodobno prepozanti poremećaj bubrežne funkcije tijekom samog 
procesa oštećenja. Također, povišene serumske vrijednosti čimbenika rasta fibroblasta 23 mogu upozoriti na nepovoljan 
ishod bubrežne ozljede. Međutim, uloga čimbenika rasta fibroblasta 23 u akutnoj bubrežnoj ozljedi je velika nepoznanica 
te su potrebna daljnja istraživanja.
Ključne riječi: Akutna ozljeda bubrega; Biološki biljezi; Čimbenik rasta fibroblasta 23; Perioperacijsko razdoblje
